Pharmacokinetics, Hemostatic Efficacy, and Safety of a New Human Fibrinogen Concentrate in Adult and Pediatric Patients with Congenital Fibrinogen Deficiency.
Claudia Djambas Khayat, Amal El-Beshlawy, Balkis Meddeb et al.
✦ AI-curated · Sources linked
In 30 seconds
This prospective, multinational, open-label, single-arm trial assessed pharmacokinetics, pharmacodynamics, surrogate efficacy, and safety of BT524 human fibrinogen concentrate in adults and children with congenital afibrinogenemia or severe hypofibrinogenemia. Twenty-seven patients received a single 70 mg/kg dose in the phase I component. Fibrinogen antigen and activity increased, and maximum clot firmness improved after infusion. In adults, mean maximum clot firmness increased by 11.1 (5.1) mm at 1 hour (P < 0.0001; 95% CI: 9.33-14.47). Treatment-related adverse events were rare, with no thromboembolic, hypersensitivity, or allergic events observed.
Key findings
- Among 27 treated patients, fibrinogen antigen and activity increased after a single 70 mg/kg dose.
- In adults, maximum clot firmness increased by 11.1 (5.1) mm at 1 hour (P < 0.0001; 95% CI: 9.33-14.47).
- In pediatric patients, mean maximum clot firmness increase ranged from 9.3 to 16.5 mm.
- One mild treatment-related increase in fibrin D-dimer was reported; no thromboembolic events, hypersensitivity, or allergic reactions were observed.
Why it matters
Congenital fibrinogen deficiency can require replacement therapy, and this trial provides pharmacokinetic and surrogate hemostatic data for a human fibrinogen concentrate in both adults and children. The observed increases in fibrinogen measures and clot firmness, alongside the reported safety findings, inform understanding of BT524, although the evidence comes from a small, single-arm study and does not establish comparative clinical benefit.
What to keep in mind
The trial was open-label and single-arm, with 27 patients; efficacy was assessed using surrogate measures, and the abstract does not report comparative clinical outcomes.